Fusion Antibodies PLC
LSE:FAB
Fusion Antibodies PLC
LSE:FAB
Price:
3.65 GBX
-2.67%
Market Closed
Updated:
Apr 28, 2024
Fusion Antibodies PLC
Cost of Revenue
|
Fusion Antibodies PLC
Cost of Revenue Peer Comparison
Comparables:
ONT
O
ORPH
DXRX
ERGO
HVO
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Fusion Antibodies PLC
LSE:FAB
|
Cost of Revenue
-£1.7m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
Cost of Revenue
-£79.2m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
O
|
Open Orphan PLC
LSE:ORPH
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Diaceutics PLC
LSE:DXRX
|
Cost of Revenue
-£2.8m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Ergomed PLC
LSE:ERGO
|
Cost of Revenue
-£90.2m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
hVIVO PLC
LSE:HVO
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Fusion Antibodies PLC's Cost of Revenue?
Cost of Revenue
-1.7m
GBP
-1.7m
GBP
Based on the financial report for Sep 30, 2023, Fusion Antibodies PLC's Cost of Revenue amounts to -1.7m GBP.
What is Fusion Antibodies PLC's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-8%
-8%
Over the last year, the Cost of Revenue growth was 28%. The average annual Cost of Revenue growth rates for Fusion Antibodies PLC have been 7% over the past three years , -8% over the past five years .
You don't have any saved screeners yet
